Ameriprise’s SELLAS Life Sciences SLS Stock Holding History

Ameriprise’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-96,692	Closed	-$645K	–	3983
2022 Q1	$645K	Buy	96,692 +2,237	+2%	+$13.1K	﹤0.01%	3394
2021 Q4	$522K	Buy	+94,455	New	+$715K	﹤0.01%	3510

Other funds holding SLS

EAM

Empery Asset Management New York $86.5M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ameriprise's SLS Position: Q2 2022 in Review

Ameriprise sold out of SELLAS Life Sciences (SLS) in Q2 2022, closing a stake of 96,692 shares — an estimated $645K sold.

Ameriprise first reported a position in SLS in Q4 2021 and held it in 2 quarters. The position peaked at $645K in Q1 2022. 26 funds tracked by Wall St. Rank hold SLS as of Q2 2022.

Ameriprise reported no remaining SELLAS Life Sciences position as of Q2 2022 after selling out during the quarter.
Ameriprise sold 96,692 SELLAS Life Sciences shares in Q2 2022, an estimated $645K.
Ameriprise first reported a position in SELLAS Life Sciences in Q4 2021 and held it in 2 quarters.
Ameriprise's SELLAS Life Sciences position peaked at $645K in Q1 2022.
26 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.